Strategic partnerships Opportunity to co-develop and leverage SARomics crystallography and NMR expertise with pharma and biotech partners, especially given recent collaborations with Coegin Pharma and Lund University, signaling a readiness to engage in joint drug discovery and fragment screening programs.

Fragment screening Sell WAC fragment screening and crystallographic fragment screening as a differentiator for early lead identification, supported by proprietary fragment libraries and established experience in fragment-based approaches.

Structure determination Offer rapid protein and protein-ligand structure determination services to shorten hit-to-lead timelines, highlighting access to a library of 600+ ready-to-express constructs and proximity to MAX IV for synchrotron-based MX data.

Antibody stability Position capabilities in antibody-antigen 3D structure determination and higher order structure analyses as a value-add for biosimilars developers and biologics firms focused on comparability and regulatory readiness.

Integrated drug discovery Promote end-to-end capabilities including computational chemistry, virtual screening, and pharmacophore-based screening alongside experimental MX and NMR services to attract full-scope discovery programs seeking a single, integrated partner.